𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Malignant melanoma in early Parkinson's disease: The DATATOP trial

✍ Scribed by Radu Constantinescu; Megan Romer; Karl Kieburtz

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
53 KB
Volume
22
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The available epidemiological data on the incidence of malignant melanoma in Parkinson's disease are contradictory. The role of levodopa therapy in this context has been debated. We identified all known cases of malignant melanoma (N = 5) in the DATATOP clinical trial cohort and compared that to published expected values (N = 1.5) for a standard healthy population. The standardized event ratio was 3.3 (95% confidence interval, 1.1–7.8), indicating that incidence of malignant melanoma was higher than expected. We found no association between levodopa therapy and the incidence of melanoma. © 2007 Movement Disorder Society

📜 SIMILAR VOLUMES

Predictors of deterioration in health-re
Predictors of deterioration in health-related quality of life in Parkinson's disease: Results from the DATATOP trial
✍ Connie Marras; Michael P. McDermott; Paula A. Rochon; Caroline M. Tanner; Gary N 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 1 views

## Abstract The aim of this study was to investigate factors associated with decline in health‐related quality of life in Parkinson's disease, by a retrospective cohort study from referral centers in Canada and the United States. Subjects were patients with early Parkinson's disease (N = 362) enrol

A randomized, double-blind trial of tran
A randomized, double-blind trial of transcranial electrostimulation in early Parkinson's disease
✍ Holly A. Shill; Sanja Obradov; Yakov Katsnelson; Ray Pizinger 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

## Abstract We studied the effects of noninvasive transcranial electrical stimulation on the motor and psychological symptoms of early Parkinson's disease. Twenty‐three subjects were treated with 10 days of placebo versus active treatment and then followed for 14 weeks. Baseline off medication Unif

Pardoprunox in early Parkinson's disease
Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double-blind trials
✍ Cristina Sampaio; Juliana Bronzova; Robert A. Hauser; Anthony E. Lang; Olivier R 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB 👁 1 views

## Abstract This report presents the results of 2 randomized trials—Rembrandt and Vermeer—on the efficacy and safety of pardoprunox in patients with early Parkinson's disease. Patients with Parkinson's disease with a Unified Parkinson's Disease Rating Scale–Motor score ≥ 10 and modified Hoehn and Y

Test–Retest reliability of the Unified P
Test–Retest reliability of the Unified Parkinson's Disease Rating Scale in patients with early Parkinson's disease: Results from a multicenter clinical trial
✍ Andrew Siderowf; Michael McDermott; Karl Kieburtz; Karen Blindauer; Sandra Plumb 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 1 views

Our objective was to assess the test-retest reliability of the Unified Parkinson's Disease Rating Scale (UPDRS). The UPDRS is the most widely used instrument for measuring severity of parkinsonian symptoms in clinical research and in practice. The validity and inter-rater reliability of this scale h

Randomized trial of the triple monoamine
Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease
✍ Robert A. Hauser; Laurence Salin; Nolwenn Juhel; Victor L. Konyago 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB

## Abstract The objective of this study was to evaluate the efficacy and safety of three daily dosages of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) compared to placebo as monotherapy in early Parkinson's disease (PD). In MPTP (1‐methyl 4‐phenyl‐tetrahydropyridine 1,2,3,6)‐lesion